
MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

